BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25072640)

  • 1. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
    Chow SC; Hsieh TC; Chi E; Yang J
    J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of the bayesian prior information to evaluation of equivalence of similar biological medicinal products.
    Chiu ST; Liu JP; Chow SC
    J Biopharm Stat; 2014; 24(6):1254-63. PubMed ID: 25032488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.
    Shin W; Kang SH
    J Biopharm Stat; 2016; 26(2):227-39. PubMed ID: 25372220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical assessment of biosimilarity based on relative distance between follow-on biologics.
    Kang SH; Chow SC
    Stat Med; 2013 Feb; 32(3):382-92. PubMed ID: 22941672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical methods for assessment of biosimilarity using biomarker data.
    Chow SC; Lu Q; Tse SK; Chi E
    J Biopharm Stat; 2010 Jan; 20(1):90-105. PubMed ID: 20077251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for individual bioequivalence inference.
    Chiang C; Hsiao CF; Liu JP
    PLoS One; 2014; 9(10):e109746. PubMed ID: 25310592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins.
    Li Y; Liu Q; Wood P; Johri A
    Stat Med; 2013 Feb; 32(3):393-405. PubMed ID: 22991275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.
    Zhang N; Yang J; Chow SC; Endrenyi L; Chi E
    Stat Med; 2013 Feb; 32(3):424-33. PubMed ID: 22933127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.